Anti-TNFα antibody versus non-anti-TNFα molecular agents for ulcerative colitis patients who failed initial anti-TNFα therapy.
Kengo KanayamaJun KatoWataru ShiratoriAriki NagashimaYuki OhtaTakashi TaidaKeiko SaitoChihiro GotoSatsuki TakahashiRyosuke HorioAkane KurosugiTsubasa IshikawaTatsuya KanekoNaoki AkizueKenichiro OkimotoTomoaki MatsumuraNaoya KatoPublished in: Journal of gastroenterology and hepatology (2022)
Non-ATA may be suitable in UC patients as the subsequent biologics regardless of the outcome of the first ATA.